Search Result

Results for "

PD-1 inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	PD-1/PD-L1 (109) Adenosine Receptor (1) Apoptosis (6) Aryl Hydrocarbon Receptor (3) Bcr-Abl (2) c-Fms (2) c-Kit (2) c-Met/HGFR (1) c-Myc (1) COMT (2) CTLA-4 (1) DGK (6) Discoidin Domain Receptor (2) EGFR (1) Eukaryotic Initiation Factor (eIF) (1) FLT3 (2) Glucosidase (2) HBV (3) HDAC (2) Histone Demethylase (1) IKK (1) Indoleamine 2,3-Dioxygenase (IDO) (1) Interleukin Related (1) Keap1-Nrf2 (1) Ligands for Target Protein for PROTAC (2) LRRK2 (2) MAP4K (2) Monoamine Oxidase (7) NAMPT (1) NF-κB (2) PARP (1) Phosphatase (2) PROTACs (1) STING (1) Target Protein Ligand-Linker Conjugates (2) TNF Receptor (1) Trk Receptor (2) VEGFR (2) α-synuclein (3)
By Research Areas:	Cancer (128) Infection (7) Inflammation/Immunology (43) Metabolic Disease (2) Neurological Disease (19)
Click Chemistry:	Azide (1)

158

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Click Chemistry

Targets Recommended: PD-1/PD-L1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P9902

Pembrolizumab 10+ Cited Publications MK-3475; Lambrolizumab	PD-1/PD-L1	Cancer
Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.

HY-P99144

Anti-Mouse PD-1 Antibody (RMP1-14) 4 Publications Verification	PD-1/PD-L1	Inflammation/Immunology
Anti-Mouse PD-1 Antibody is an anti-mouse *PD-1* IgG2a antibody inhibitor.

HY-P99144A

Anti-Mouse PD-1 Antibody (S-5001) 4 Publications Verification	PD-1/PD-L1	Inflammation/Immunology
Anti-Mouse PD-1 Antibody (S-5001) is an anti-mouse *PD-1* IgG1 antibody inhibitor.

HY-P9902A

Pembrolizumab (anti-PD-1) 2 Publications Verification MK-3475 (anti-PD-1); Lambrolizumab (anti-PD-1)	PD-1/PD-L1	Cancer
Pembrolizumab (anti-PD-1) is a humanized IgG4 antibody and *PD-1* inhibitor. Pembrolizumab produces *PD-1* blockade, preventing PD-L1 and PD-L2 from connecting to *PD-1. This avoids the uncontrolled regulation of T cells on cells that normally express PD-1* .

HY-101058A

PD1-PDL1-IN 1 TFA	PD-1/PD-L1	Inflammation/Immunology Cancer
PD1-PDL1-IN 1 TFA (compound 16) is a potent programmed cell death 1 (PD-1) inhibitor. PD1-PDL1-IN 1 TFA is useful as immune modulator .

HY-134886

PD-1-IN-24	PD-1/PD-L1	Cancer
PD-1-IN-24 (compound 1) is an orally active *PD-1* inhibitor .

HY-P99895

Rulonilimab	PD-1/PD-L1	Inflammation/Immunology Cancer
Rulonilimab is a human IgG1 monoclonal antibody against *PD-1* that targets, binds and inhibits PD-1 and its downstream signalling pathways with potential immune checkpoint inhibition and anti-tumour activity .

HY-101058

PD1-PDL1-IN 1	PD-1/PD-L1	Inflammation/Immunology
PD1-PDL1-IN 1 (compound 16) is a potent programmed cell death 1 (PD-1) inhibitor. PD1-PDL1-IN 1 is useful as immune modulator .

HY-162343

PD-1/PD-L1-IN-41	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-1/ PD-L1-in-41 (Compound 5c) is a PD-L1 and *PD-1* inhibitor with IC₅₀ value of 10.2 nM .

HY-101098

PD-1-IN-18	PD-1/PD-L1	Inflammation/Immunology
PD-1-IN-18 is a *PD1* signaling pathway inhibitor, which acts as an immunomodulator.

HY-P99166

Vudalimab	PD-1/PD-L1 CTLA-4	Inflammation/Immunology Cancer
Vudalimab is a potent dual *PD-1* and CTLA-4 inhibitor as a fully humanized bispecific monoclonal antibody. Vudalimab targets immune checkpoint receptors PD-1 and CTLA-4 and promotes tumor-selective T-cell activation .

HY-157569

PD1-PDL1-IN 2	PD-1/PD-L1	Cancer
PD1-PDL1-IN 2 (ZE132) is a potent and selective *PD-1/PD-L1* inhibitor, which has robust anti-tumour activity in vivo. PD1-PDL1-IN 2 promotes cytotoxic T-cell tumour infiltration and induces IL-2 expression. In addition, PD1-PDL1-IN 2 elicits strong inhibitory effects on the mRNA expression of TGF-β .

HY-P99887

Pimivalimab JTX-4014	PD-1/PD-L1	Cancer
Pimivalimab (JTX-4014) is a *PD-1* inhibitor. Pimivalimab can be used for the research of solid tumor .

HY-P99639

Geptanolimab APL-501; CBT-501; GB-226	PD-1/PD-L1	Cancer
Geptanolimab (CBT-501) is a humanized IgG4k monoclonal antibody against programmed death-1 (PD-1). Siplizumab inhibits the binding of PD-L1/L2 to PD-1 through a competitive action. Siplizumab can be used in research of cancer .

HY-P9971

Camrelizumab 2 Publications Verification SHR-1210	PD-1/PD-L1	Cancer
Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonal antibody (mAb) to *PD-1. Camrelizumab binds PD-1* at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC₅₀ of 0.70 nM. Camrelizumab acts as anti-PD-1/PD-L1 agent and can be used for cancer research, including NSCLC, ESCC, Hodgkin lymphoma, and advanced HCC et,al .

HY-P99618

Fidasimtamab IBI-315; BH2950	EGFR PD-1/PD-L1	Inflammation/Immunology Cancer
Fidasimtamab (IBI-315; BH2950) is a recombinant human IgG1 bispecific antibody that targets, binds and inhibits both HER2 and *PD-1* and their downstream signalling pathways, and links PD-1 expressing T cells to HER2 expressing tumour cells. Fidasimtamab has potential immunosuppressive and antitumor activity .

HY-101097

PD-1-IN-17	PD-1/PD-L1	Cancer
PD-1-IN-17 is a programmed cell death-1 (PD-1) inhibitor extracted from patent WO2015033301A1, Compound 12, inhibits 92% splenocyte proliferation at 100 nM .

HY-19991

BMS-1 Maximum Cited Publications 23 Publications Verification PD-1/PD-L1 inhibitor 1	PD-1/PD-L1 Apoptosis	Inflammation/Immunology Cancer
BMS-1 is an inhibitor of the *PD-1/PD-L1* protein/protein interaction (IC₅₀ between 6 and 100 nM) .

HY-P99499

Cetrelimab JNJ 63723283; JNJ 3283	PD-1/PD-L1 Interleukin Related TNF Receptor	Cancer
Cetrelimab (JNJ 63723283; JNJ 3283) is a human IgG4κ mAb targeting *PD-1. Cetrelimab binds PD-1* (K_d=1.72 nM, HEK293) to block the interaction of *PD-1* with PD-L1 and PD-L2 (IC₅₀s=111.7 ng/mL and 138.6 ng/mL, respectively). Cetrelimab stimulates peripheral T cells, increases IFN-γ, IL-2, TNF-α level and inhibits tumor growth in vivo .

HY-101097A

PD-1-IN-17 TFA	PD-1/PD-L1	Cancer
PD-1-IN-17 TFA is a programmed cell death-1 (PD-1) inhibitor extracted from patent WO2015033301A1, Compound 12, inhibits 92% splenocyte proliferation at 100 nM .

HY-101093B

PD-1-IN-20	PD-1/PD-L1	Cancer
PD-1-IN-20 is the less active enantiomer of PD-1-IN-1. PD-1-IN-1 is an inhibitor of programmed cell dealth-1 (PD-1) extracted from patent WO 2015033299 A1, compound example 4 .

HY-P10217

PD-1/PD-L1-IN-42	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-42 (Compound B8.4) is an inhibitor of the interaction between PD-1 and PD-L1, with an EC₅₀ of 0.1 μM. PD-1/PD-L1-IN-42 can be used for the research of cancer immunotherapy .

HY-N12537

PD-1/PD-L1-IN-38	PD-1/PD-L1	Cancer
PD-1/ PD-L1-in-38 is a *PD-1/PD-L1* inhibitor, which can inhibit the proliferation of tumor cells, promote the secretion of INF-γ by CD8 ⁺ T cells, and inhibit the ability of PD-1/PD-L1 signal transduction. PD-1/PD-L1-IN-38 has antitumor activity .

HY-P4072

(D)-PPA 1	PD-1/PD-L1	Cancer
(D)-PPA 1 is a hydrolysisresistant d-peptide antagonist. (D)-PPA 1 serves as a potent *PD-1/PD-L1* inhibitor. (D)-PPA 1 binds to PD-1 with the affinity 0f 0.51 μM with in vitro and in vivo efficacy .

HY-155101

PD-L1-IN-3	PD-1/PD-L1	Cancer
PD-L1-IN-3 (Compound 4a) is a compound that targets PD-1/PD-L1, the IC₅₀ value and EC₅₀ value is 4.97nM and 2.70 μM for inhibit PD-L1 and Jurkat T cells, respectively. PD-L1-IN-3 can bind PD-L1 dimer to prevent PD-1 binding to PD-L1, therefore blocking PD-1 signaling. PD-L1-IN-3 can be used for lung cancer and melanoma diseases research .

HY-116274

BMS-8	PD-1/PD-L1	Cancer
BMS-8 inhibits the *PD-1/PD-L1* interaction with IC₅₀ of 7.2 μM. BMS-8, binds directly to PD-L1 and induces formation of PD-L1 homodimers, which in turn prevents the interaction with PD-1 .

HY-P4072A

(D)-PPA 1 TFA	PD-1/PD-L1	Cancer
(D)-PPA 1 TFA is a hydrolysisresistant d-peptide antagonist. (D)-PPA 1 TFA serves as a potent *PD-1/PD-L1* inhibitor. (D)-PPA 1 TFA binds to PD-1 with the affinity 0f 0.51 μM with in vitro and in vivo efficacy .

HY-P2478

Human PD-L1 inhibitor V	PD-1/PD-L1	Inflammation/Immunology
Human PD-L1 inhibitor V, a *human PD-1* protein binding peptide with a K_d** value of 3.32 μM. Human PD-L1 inhibitor V inhibit the interaction of hPD-1/hPD-L1 .

HY-P2477

Human PD-L1 inhibitor IV	PD-1/PD-L1	Inflammation/Immunology
Human PD-L1 inhibitor IV, a polypeptide, is a competitive *human PD-1* protein** inhibitor with a K_d value of 1.38 μM. Human PD-L1 inhibitor IV inhibits the interaction of hPD-1/hPD-L1 .

HY-P99048

Sintilimab IBI308	PD-1/PD-L1	Inflammation/Immunology Cancer
Sintilimab (IBI308) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to *PD-1* with a K_D value of 74 pM. Sintilimab blocks the interaction of *PD-1* with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer .

HY-102011

BMS-1166 3 Publications Verification	PD-1/PD-L1	Inflammation/Immunology Cancer
BMS-1166 is a potent *PD-1/PD-L1* immune checkpoint inhibitor. BMS-1166 induces dimerization of PD-L1 and blocks its interaction with PD-1, with an IC₅₀ of 1.4 nM. BMS-1166 antagonizes the inhibitory effect of PD-1/PD-L1 immune checkpoint on T cell activation .

HY-102011A

BMS-1166 hydrochloride 3 Publications Verification	PD-1/PD-L1	Inflammation/Immunology Cancer
BMS-1166 hydrochloride is a potent *PD-1/PD-L1* immune checkpoint inhibitor. BMS-1166 hydrochloride induces dimerization of PD-L1 and blocks its interaction with PD-1, with an IC₅₀ of 1.4 nM. BMS-1166 hydrochloride antagonizes the inhibitory effect of PD-1/PD-L1 immune checkpoint on T cell activation .

HY-P99610

Ezabenlimab BI-754091	PD-1/PD-L1	Cancer
Ezabenlimab (BI-754091) is an anti-PD-1 mAb with binding constant K_d value of 6 nM (CHO cells). Ezabenlimab blocks the interaction of *PD-1* with PD-L1 and PD-L2. Ezabenlimab increases interferon-γ secretion in T cells, and inhibits tumor growth in vivo .

HY-155959

PD-1/PD-L1-IN-33	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-33 (Compound N11) is a *PD-1/PD-L1* inhibitor. PD-1/PD-L1-IN-33 inhibits PD-1 and PD-L1 interaction with an IC₅₀: 6.3 nM. PD-1/PD-L1-IN-33 promotes T-cell proliferation, activation, and infiltration into tumor spheres. PD-1/PD-L1-IN-33 has immunomodulatory and anticancer activity .

HY-P2478A

Human PD-L1 inhibitor V TFA	PD-1/PD-L1	Inflammation/Immunology
Human PD-L1 inhibitor V TFA, a *human PD-1* protein binding peptide with a K_d** value of 3.32 μM. Human PD-L1 inhibitor V TFA inhibit the interaction of hPD-1/hPD-L1 .

HY-P99345

Dostarlimab TSR-042	PD-1/PD-L1	Cancer
Dostarlimab (TSR-042) is a humanized anti-PD-1 monoclonal antibody. Dostarlimab binds with high affinity to human PD-1 and competitively inhibits its interaction with its ligands, PD-L1 and PD-L2, with IC₅₀s of 1.8 and 1.5 nM, respectively .

HY-163307

PD-1/PD-L1-IN-39	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-39 (X 14) is an orally active *PD-1/PD-L1* inhibitor with a IC₅₀ value of 15.73 nM. PD-1/ PD-L1-in-39 has a good binding affinity for human and mouse PD-L1, with K_D values of 14.62 nM and 392 nM, respectively. PD-1/PD-L1-IN-39 has antitumor activity .

HY-156573

DGKα&ζ-IN-1	DGK	Cancer
DGKα&ζ-IN-1 (Compound II) is a DGK target inhibitor. DGKα&ζ-IN-1 can enhance the function of T cells, and has a synergistic effect with PD-1, which has therapeutic effects IN both immune and tumor .

HY-168081

PD-1/PD-L1-IN-52	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-52 (Compound III-5) is an orally active *PD-1/PD-L1* inhibitor that blocks the interaction between PD-1 and PD-L1, with an IC₅₀ of 109.9 nM. PD-1/PD-L1-IN-52 exhibits antitumor activity in a C57BL/6 mouse xenograft model implanted with human PD-1-expressing MC38 colon cancer cells, with a TGI of 49.6% .

HY-163534

PD-1/PD-L1-IN-43	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-43 (compound Z13) is a small-molecule inhibitors targeting the *PD-1/PD-L1* interaction. PD-1/PD-L1-IN-43 exhibites potent in vivo antitumor efficacy against B16-F10 melanoma. PD-1/PD-L1-IN-43 inhibits tumor growth by blocking the interaction between *PD-1* and PD-L1. PD-1/PD-L1-IN-43 can be used in anti-tumor studies .

HY-158050

PXB17	c-Fms	Cancer
PXB17 can inhibit CSF1R (IC₅₀ = 1.7 nM) by blocking the activation of PI3K/ AKT/mTORC1 signaling. PXB17 is orally effective. PXB17 significantly inhibits the growth of CRC, improves PD-1 mAb efficacy and reduces tumor recurrence in CRC .

HY-129600

MYCi361 2 Publications Verification NUCC-0196361	c-Myc	Cancer
MYCi361 (NUCC-0196361) is a MYC inhibitor with the K_d of 3.2 μM for binding to MYC. MYCi361 (NUCC-0196361) suppresses tumor growth and enhances anti-PD1 immunotherapy .

HY-103048

PD-1/PD-L1-IN 3	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN 3, a macrocyclic peptide, is a potent and selective inhibitor of the *PD-1/PD-L1* and CD80/PD-L1 interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC₅₀s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 can be used for the research of various diseases, including cancer and infectious diseases .

HY-103048A

PD-1/PD-L1-IN 3 TFA	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN 3 TFA, a macrocyclic peptide, is a potent and selective inhibitor of the *PD-1/PD-L1* and CD80/PD-L1 interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 TFA interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC₅₀s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 TFA can be used for the research of various diseases, including cancer and infectious diseases .

HY-145240

eIF4E-IN-1	Eukaryotic Initiation Factor (eIF)	Infection Cancer
eIF4E-IN-1 is a potent inhibitor of eIF4E. eIF4E-IN-1 inhibits immunosuppression components such as immune checkpoint proteins PD-1, PD-L1, LAG3, TIM3, and/or IDO, in order to inhibit or release immune suppression in certain diseases, such as cancer and infectious disease (extracted from patent WO2021003194A1, compound Y) .

HY-153358

TNG260	HDAC	Cancer
TNG260 is a CoREST-selective deacetylase (CoreDAC) inhibitor. TNG260 inhibits HDAC1 with 10-fold selectivity over HDAC3. TNG260 leads to HDAC1 inhibition, reverses anti-PD1 resistance driven by loss of STK11. TNG260 decreases intratumoral infiltration of neutrophils. TNG260 exhibits immune-mediated cell killing .

HY-16961

Sitravatinib 3 Publications Verification MGCD516; MG-516	VEGFR c-Kit FLT3 Discoidin Domain Receptor Trk Receptor	Inflammation/Immunology Cancer
Sitravatinib (MGCD516) is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor with IC₅₀s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively . Sitravatinib shows potent single-agent antitumor efficacy and enhances the activity of PD-1 blockade through promoting an antitumor immune microenvironment .

HY-16961A

Sitravatinib malate MGCD516 malate; MG-516 malate	VEGFR c-Kit FLT3 Discoidin Domain Receptor Trk Receptor	Inflammation/Immunology Cancer
Sitravatinib malate (MGCD516 malate) is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor with IC₅₀s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively . Sitravatinib malate shows potent single-agent antitumor efficacy and enhances the activity of PD-1 blockade through promoting an antitumor immune microenvironment .

HY-128679

TBK1/IKKε-IN-5	IKK	Cancer
TBK1/IKKε-IN-5 (compound 1) is an orally active TBK1 and IKKε dual inhibitor, with IC₅₀ values of 1 and 5.6 nM, respectively. TBK1/IKKε-IN-5 enhances the blockade response to *PD-1* and induces immune memory in rats when combines with anti-PD-L1. TBK1/IKKε-IN-5 can be used in cancer research, especially in tumour immunity .

HY-153358A

(S)-TNG260	HDAC	Cancer
(S)-TNG260 is an isomer of TNG260 (HY-153358). TNG260 is a CoREST selective deacetylase (CoreDAC) inhibitor. TNG260 inhibits HDAC1 with 10-fold selectivity over HDAC3. TNG260 causes HDAC1 inhibition and reverses anti-PD1 resistance driven by STK11 deletion. TNG260 reduces intratumoral infiltration of neutrophils. TNG260 exhibits immune-mediated cell killing.

Cat. No.	Product Name

HY-L031

Small Molecule Immuno-Oncology Compound Library

535 compounds

Immuno-Oncology is a type of immunotherapy that has the specific purpose of treating cancer. It works by stimulating our immune system to fight back. Normally, our immune system is able to destroy cancer cells in our body, however sometimes cancer cells can adapt and mutate, effectively hiding from our immune system. This is when tumors can develop and become a threat to our health. Immuno-oncology involves mobilizing lymphocytes to recognize and eliminate cancer cells using the body’s immune system. There are several immuno-oncology treatments available, including Immune cell therapy (CAR-T), monoclonal antibodies (mABs) and checkpoint inhibitors, cytokines and cancer vaccines.

MCE Small Molecule Immuno-Oncology Compound Library offers 535 bioactive tumor immunology compounds that target some important checkpoints such as PD1/PD-L1, CXCR, Sting, IDO, TLR, etc. This library is a useful tool for Immuno-oncology research.

HY-L109

Protein-protein Interaction Inhibitor Library

616 compounds

Protein protein interactions (PPI) have pivotal roles in life processes. The studies showed that aberrant PPI are associated with various diseases, including cancer, infectious diseases, and neurodegenerative diseases. The classic drug targets are usually enzymes, ion channels, or receptors, the PPI indicate new potential therapeutic targets. Therefore, targeting PPI is a new direction in treating diseases and an essential strategy for the development of new drugs.

However, the design of modulators targeting PPI still faces tremendous challenges, such the difficult PPI interfaces for the drug design, lack of ligands reference, lack of guidance rules for the PPI modulators development and high-resolution PPI proteins structures.

With the development of high-throughput technology, high-throughput screening is also gradually used for the identification of PPI inhibitors, but the compound library used for conventional target screening is not very effective in screening PPI inhibitors. To improve screening efficiency, MCE carefully selected 616 PPI inhibitors and mainly targeting MDM2-p53, Keap1-Nrf2, PD-1/PD-L1, Myc-Max, etc. MCE Protein-protein Interaction Inhibitor Library is a useful tool for PPI drug discovery and related research.

Cat. No.	Product Name	Target	Research Area